%0 Journal Article
%T 先天细胞毒性淋巴细胞在肺癌PD-1/PD-L1抑制剂治疗中的作用<br>The Role of Congenital Cytotoxic Lymphocytes in PD-1/PD-L1 Inhibitor Treatment of Lung Cancer
%A 袁坤飞
%A 曹冉华
%J Advances in Clinical Medicine
%P 1009-1015
%@ 2161-8720
%D 2024
%I Hans Publishing
%R 10.12677/acm.2024.14123179
%X 免疫治疗是治疗肺癌的重要方式之一。先天毒性淋巴细胞与肺癌免疫治疗的预后相关&#65292;在肺癌免疫治疗的患者选择和预后评估中发挥重要作用&#65292;可以指导肺癌患者的免疫治疗和管理。本文中&#65292;我们简要总结先天细胞毒性淋巴细胞在肺癌免疫调节中的作用&#65292;重点关注先天细胞毒性淋巴细胞对肺癌PD-1/PD-L1抑制剂治疗疗效的预测作用。<br>Immunotherapy is one of the important ways to treat lung cancer. The prevalence of innate cytotoxic lymphocytes is related to the prognosis of lung cancer immunotherapy, and it plays an important role in the selection of patients for lung cancer immunotherapy and the evaluation of prognosis, which can guide the immunotherapy and management of lung cancer patients. In this article, we briefly summarize the role of innate cytotoxic lymphocytes in lung cancer immune regulation and focus on the predictive effect of innate cytotoxic lymphocytes on the efficacy of PD-1/PD-L1 inhibitors in lung cancer.
%K 先天细胞毒性淋巴细胞&#65292
%K PD-1/PD-L1抑制剂&#65292
%K 肺癌<br>Congenital Cytotoxic Lymphocytes
%K PD-1/PD-L1 Inhibitors
%K Lung Cancer
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=103283